News Article | August 8, 2017
The GLUCOCARD Shine XL BGMS was introduced at the American Association of Diabetes Educators (AADE) meeting last week in Indianapolis, IN. The AADE is the largest gathering of diabetes educators in the US and ARKRAY is a sponsor of the meeting. "The release of the GLUCOCARD Shine XL expands ARKRAY's family of Shine BGMS," said ARKRAY President Jonathan Chapman. "With the introduction of the GLUCOCARD Shine XL, ARKRAY now has one of the broadest lines of BGMS' in the industry. This provides more choices for people living with diabetes and the healthcare professionals who care for them." The GLUCOCARD Shine XL uses the same test strips as the previously launched GLUCOCARD Shine BGMS, which has been proven in numerous studies to provide highly accurate test results while being easy to use.1 Diabetes, or diabetes mellitus, is a metabolic type of disease in which affected people have high blood glucose (blood sugar), either because insulin production is inadequate (Type 2), or because the islet cells in the pancreas no longer produce insulin (Type 1, sometimes referred to as juvenile diabetes). The ADA estimates that more than 30 million Americans suffer from either Type 1 or Type 2 diabetes and that 25.9% of Americans 65 years of age or greater may have diabetes. ARKRAY USA, Inc. is a division of ARKRAY, a global leader in diabetes care with headquarters in Kyoto, Japan. For more than half a century, ARKRAY has pioneered products to ensure that people who have diabetes - and the health professionals who care for them - can better manage the condition. ARKRAY currently does business in more than 80 countries worldwide and is the market leader in diabetes management in the long-term care market in the U.S. The Company has a long history of developing cutting edge technology such as the first portable glucose analyzer available in the United States; the first HbA1C analyzer; and the first hand-held blood glucose meter. For more information, visit www.arkrayusa.com.
News Article | August 4, 2017
Built on the foundation of simple logbooks and glucose tracking, ARK Care Advance translates that information into graphs and charts to easily identify, isolate and record changes within diabetes management. The ARK Care Vita app allows tracking of glucose readings, diet and exercise anywhere. The app will be available for download for both iOS and Android devices at the end of September. Both ARK Care Advance and ARK Care Vita will be demonstrated at ARKRAY's booth at the American Association of Diabetes Educators annual meeting, which takes place today through August 7th in Indianapolis, IN. "The launch of ARK Care Advance and ARK Care Vita represents the ARKRAY commitment to contributing to the health and well-being of people living with diabetes," said ARKRAY President Jonathan Chapman. "While many companies in the diabetes marketplace are reducing their investments in research and development, ARKRAY continues to deliver new products and services to help people with diabetes live a healthier and more active life." Diabetes, or diabetes mellitus, is a metabolic type of disease in which affected people have high blood glucose (blood sugar), either because insulin production is inadequate (Type 2), or because the islet cells in the pancreas no longer produce insulin (Type 1, sometimes referred to as juvenile diabetes). The ADA estimates that more than 30 million Americans suffer from either Type 1 or Type 2 diabetes and that 25.9% of Americans 65 years of age or greater will have diabetes. ARKRAY USA, Inc. is a division of ARKRAY, a global leader in diabetes care with headquarters in Kyoto, Japan. For more than half a century, ARKRAY has pioneered products to ensure that people who have diabetes - and the health professionals who care for them - can better manage the condition. ARKRAY currently does business in more than 80 countries worldwide and is the market leader in diabetes management in the long-term care market in the U.S. The Company has a long history of developing cutting edge technology such as the first portable glucose analyzer available in the United States; the first HbA1C analyzer; and the first hand-held blood glucose meter. For more information, visit www.arkrayusa.com.
News Article | July 12, 2017
"For over 90 years, Novo Nordisk has continued to develop innovative diabetes medicines and devices. In today's environment, in order to truly improve the prospects of the 29 million people with diabetes in the US, we must aspire towards leadership in digital health that complements our research and development expertise," said David Moore, Senior VP, Marketing for Novo Nordisk Inc. "That was the catalyst to our partnership with Glooko as well as IBM Watson Health and this milestone is just the beginning. Our companies share a common vision of empowering patients with ever improving digital health solutions and we are excited about our combined capabilities and what that can do for improving diabetes treatment." Beyond the launch of the C4C app, Novo Nordisk is working with Glooko to enhance its Digital Health Platform – a diabetes management system used to store and analyze data and deliver real-time feedback to people with diabetes and their caregivers. In time, this will contribute to Novo Nordisk's ability to provide concrete guidance to patients and healthcare professionals and also demonstrate the cost effectiveness of treatments to healthcare systems. About the Cornerstones4Care Powered by Glooko App The modular app concept will initially enable people with diabetes to easily measure and track their blood glucose, activity and meals all in one place, and serve as the framework for additional jointly-developed digital tools from Novo Nordisk and Glooko. The C4C App uses Glooko's cutting-edge technology to sync a user's blood glucose and activity data from the majority of currently available diabetes and exercise devices. It also identifies pertinent trends to aid in understanding the factors that impact blood glucose levels, and includes relevant content and resources exclusively selected from Cornerstones4Care, the personalized support program for people with diabetes (Cornerstones4Care.com). The integrated offering is intended to help people learn how to better manage diabetes through their mobile devices. To gain experience and invite use, Novo Nordisk is making the new C4C app free to all patients enrolled in Cornerstones4Care.com and free for download from both the Apple and Google Play App stores. The C4C app represents another milestone in the fast growing Novo Nordisk drive to build its digital health platform, which is being developed in partnership with IBM Watson Health. Rick Altinger, CEO of Glooko said, "More people than ever are using mobile apps for chronic disease management, and the apps, like the new C4C app, go beyond data capture or tracking to providing insights and recommendations based on that data. By leveraging the expertise and capabilities of Glooko, combined with Cornerstones4Care content, we were able to build a truly unique app to better support people with diabetes." He added, "Ultimately our digital health solution will help health care practitioners gain round-the-clock insight into their patients, and empower people with diabetes to better manage their diabetes, with the aim of ultimately leading to better diabetes management outcomes." About Diabetes In the United States, more than 29 million people are affected by diabetes. Type 2 diabetes accounts for 90 to 95 percent of all diabetes cases. Diabetes is emerging as one of the most serious health problems of our time; the number of Americans with diabetes has quadrupled over the past 30 years. About Novo Nordisk Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. With U.S. headquarters in Plainsboro, N.J., Novo Nordisk Inc. has nearly 5,000 employees in the United States. For more information, visit novonordisk.us or follow us on Twitter: @novonordiskus. About Glooko Glooko is a leading diabetes data management platform and is trusted by many of the world's leaders in diabetes care. Over 1 million people with diabetes and 6,000 health systems in 27 countries use Glooko's FDA-cleared, HIPAA-compliant Mobile, Population Health and Clinic Upload applications with an aim to improve health outcomes for people with diabetes. Glooko syncs with the world's most popular diabetes devices and major fitness and activity trackers and supplies personalized, timely, verified patient data such as blood glucose, food, insulin, blood pressure, diet and weight data.
News Article | July 10, 2017
INDIANAPOLIS and RIDGEFIELD, Conn., July 10, 2017 /PRNewswire/ -- Popular television host and legendary entertainer, Don Francisco, is joining Lilly and Boehringer Ingelheim to launch a new awareness initiative, Basado en Hechos, to help address common misconceptions about type 2 diabetes...
News Article | September 29, 2017
Many adults with type 1 and type 2 diabetes struggle with blood sugar control after meals. The result of this has led to many people with diabetes not achieving their target A1C. "With Fiasp®, we've built on the insulin aspart molecule to create a new treatment option to help patients meet their post-meal blood sugar target," said Bruce Bode, MD FACE, President of Atlanta Diabetes Associates and Associate Professor at Emory University School of Medicine. "The intention of rapid acting insulin therapy is to mimic, as much as possible, the natural physiological insulin response that occurs after meals, a process that is important for optimal A1C management." Fiasp® will launch at the same list price as NovoLog® and will be offered with a Savings Card program for eligible patients with commercial insurance to reduce co-pays. Fiasp® will also be available to eligible patients through the Novo Nordisk Patient Assistance Program. Patients and caregivers can obtain more information and access to the Novo Nordisk Patient Assistance Program by calling toll free at 866-310-7549. The approval of Fiasp® is based on results from the onset phase 3a clinical development program. The clinical trials enrolled more than 2,000 adults with type 1 and type 2 diabetes to evaluate the efficacy and safety of Fiasp® administered both at mealtime and after starting a meal. Data from the trials showed that Fiasp® demonstrated a reduction in A1C in adults with type 1 and type 2 diabetes.1 Common adverse reactions, excluding hypoglycemia, occuring in ≥5% of subjects included nasopharyngitis, upper respiratory tract infection, nausea, diarrhea and back pain.1 Do not share your FIASP with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them. Who should not take FIASP? Do not take FIASP if you: Before taking FIASP, tell your healthcare provider about all your medical conditions including, if you: Before you start taking FIASP, talk to your healthcare provider about low blood sugar and how to manage it. How should I take FIASP? What should I avoid while taking FIASP? While taking FIASP do not: What are the possible side effects of FIASP? FIASP may cause serious side effects that can lead to death, including: Your insulin dose may need to change because of: Treatment with TZDs and FIASP may need to be adjusted or stopped by your healthcare provider if you have new or worse heart failure. Common side effects of FIASP may include: These are not all the possible side effects of FIASP. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of FIASP. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about FIASP that is written for health professionals. Do not use FIASP for a condition for which it was not prescribed. Do not give FIASP to other people, even if they have the same symptoms that you have. It may harm them. What are the ingredients in FIASP? Active Ingredient: insulin aspart Inactive Ingredients: glycerol, phenol, metacresol, zinc, disodium phosphate dihydrate, arginine hydrochloride, niacinamide and water for injections Manufactured by: Novo Nordisk A/S DK-2880 Bagsvaerd, Denmark For more information, go to www.novonordisk-us.com or call 1-800-727-6500. This Patient Information has been approved by the U.S. Food and Drug Administration Please see Prescribing Information at http://www.novo-pi.com/fiasp.pdf. About Diabetes In the United States, more than 30 million people are affected by diabetes. Type 2 diabetes accounts for 90 to 95 percent of all diabetes cases.3 Diabetes is emerging as one of the most serious health problems of our time; the number of Americans with diabetes has quadrupled over the past 30 years.4 About Novo Nordisk Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. With U.S. headquarters in Plainsboro, N.J., Novo Nordisk Inc. has nearly 5,000 employees in the United States. For more information, visit novonordisk.us or follow us on Twitter: @novonordiskus. Fiasp®, NovoLog® and FlexTouch® are registered trademarks of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2017 Novo Nordisk All rights reserved. USA17INS02464 September 2017
News Article | February 27, 2017
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces the completion of enrollment in the Company’s Phase 2 clinical trial with its novel, small-molecule glucagon receptor antagonist LGD-6972 for the treatment of type 2 diabetes mellitus (T2DM). This randomized, double-blind, placebo-controlled study is evaluating the safety and efficacy of LGD-6972 as an adjunct to diet and exercise in subjects with T2DM whose blood glucose levels are inadequately controlled with metformin. The Company expects to report topline results in September 2017. In this Phase 2 study, subjects with T2DM are being treated with one of three doses of LGD-6972 (5 mg, 10 mg, or 15 mg) or placebo once daily for 12 weeks. The primary endpoint is change from baseline in hemoglobin A1c (HbA1c). Secondary endpoints include change from baseline in fasting plasma glucose, insulin, glucagon and GLP-1, as well as changes in lipids, blood pressure and body weight. In a subset of subjects, an oral glucose tolerance test is also being conducted at baseline and at the end of treatment. “We are pleased with the rapid enrollment of patients, an accomplishment that enables us to report topline data by the end of the third quarter of 2017, ahead of our timeline projections,” said John Higgins, Chief Executive Officer. “Antagonism of the glucagon pathway is one of the most promising new therapeutic approaches for type 2 diabetes, and we believe LGD-6972 has potential valuable therapeutic properties. We look forward to obtaining data later this year, and to exploring potential partnerships for this program, consistent with our shots-on-goal business model.” Based on Phase 1 trial results that were published in Diabetes, Obesity and Metabolism in January 20171, Ligand believes LGD-6972 holds potential to have promising and differentiating properties given its potency in lowering plasma glucose in patients with T2DM and its preliminary safety profile. Glucagon is a hormone produced by the pancreas that stimulates the liver to produce glucose (sugar). Overproduction of glucose by the liver is an important cause of high glucose levels in patients with T2DM and is believed to be due in part to inappropriately elevated levels of glucagon. Glucagon receptor antagonists (GRA) are designed to lower glucose levels by reducing the production of glucose by the liver. GRAs are novel molecules that have demonstrated a reduction of glucose and HbA1c in mid-stage clinical trials. Preclinical studies have shown that LGD-6972 is highly potent and selective, that it inhibits glucagon-induced hyperglycemia in both rats and monkeys and that it also significantly lowers glucose in a mouse model of T2DM. Additionally, LGD-6972 significantly lowered fasting and non-fasting glucose levels in a mouse model of type 1 diabetes and reduced HbA1c, ketone bodies and free fatty acids. LGD-6972 also has been shown to have additive effects when used in combination with insulin therapy and may be useful in an insulin-sparing regimen. Diabetes is a growing global epidemic that as of 2015 affected more than 415 million people worldwide2. In North America, approximately 44 million people have diabetes2. If current trends continue, by 2050 fully 33% of the U.S. population will be affected3. People with T2DM either are resistant to the effects of insulin or do not produce enough insulin to maintain a normal glucose level. Sustained high glucose levels can cause diabetic complications such as heart disease, stroke, kidney failure, neuropathy, lower-limb amputations and blindness. Although T2DM is more common in adults, it increasingly affects children as childhood obesity increases. An estimated 90% to 95% of Americans with diabetes have T2DM4. The global market for diabetes drugs is expected to nearly double to $68 billion by 20225 as treatment paradigms shift toward combination therapies and novel non-insulin drugs. Global sales of the top 10 non-insulin diabetes drugs exceeded $15 billion in 2016 and are expected to increase to $20 billion by 20206. Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligand’s Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. OmniAb® is a patent-protected transgenic animal platform used in the discovery of fully human mono-and bispecific therapeutic antibodies. Ligand has established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Novartis, Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter International and Eli Lilly. This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. These include statements regarding the timing of the release of topline results from the Phase 2 clinical trial of LGD-6972 with subjects with T2DM, the potential for LGD-6972 to treat patients with T2DM, the potential for LGD-6972 to exhibit best-in-class properties, Ligand’s ability to partner the program in the future, the number of patients affected by diabetes, the annual total sales of non-insulin diabetes drugs and the expected future sales of such drugs. Actual events or results may differ from our expectations. For example, patients in the Phase 2 clinical trial could drop out during the course of treatment which require additional enrollment to complete the Phase 2 clinical trial; the timing of the data from our third party clinical contractors could be delayed due to circumstances beyond Ligand’s control; Ligand could require additional time to analyze the data prior to release; the clinical trial could fail to reach its primary or secondary endpoints which could result in Ligand’s inability to partner the program; and the safety and tolerability data from a new clinical trial in LGD-6972 may conflict with the results of the Phase 1 clinical trials; the number of patients diagnosed with diabetes may be more or fewer than Ligand believes; and the total sales of non-insulin diabetes drugs is dependent on market acceptance of such drugs. The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price. Additional information concerning these and other important risk factors affecting Ligand can be found in Ligand's prior press releases available at www.ligand.com as well as in Ligand's public periodic filings with the Securities and Exchange Commission, available at www.sec.gov. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this press release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. 1. Eric G. Vajda, et al. Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus, Diabetes Obes Metab 2017; 19(1):24–32. 3. James P Boyle, et al. Projection of the year 2050 burden of diabetes in the U.S. adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. American Diabetes Association, Population Health Metrics. 2010 Oct 22;8:29
News Article | December 15, 2016
INDIANAPOLIS and RIDGEFIELD, Conn., Dec. 15, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim Pharmaceuticals, Inc. announced today that BASAGLAR® (insulin glargine injection 100 units/mL) is available by prescription in the U.S. BASAGLAR is a follow-on...
News Article | November 10, 2016
SAN DIEGO, Nov. 10, 2016 /PRNewswire/ -- Today, Dexcom, Inc. (NASDAQ:DXCM), a provider of continuous glucose monitoring (CGM) for patients with Type 1 Diabetes, announced that it has teamed up with professional soccer player Jordan Morris of Seattle Sounders FC, who will share his...
News Article | December 13, 2016
INDIANAPOLIS, Dec. 13, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that people who use Lilly insulin will be able to access discounted prices for their purchases starting January 1, 2017 via mobile and web platforms hosted by Blink Health. The discounts,...
American Journal Geriatric Pharmacotherapy | Year: 2011
Background: Most elderly patients with type 2 diabetes require, or will eventually require, insulin to achieve or maintain their glycemic goals. However, insulin therapy remains underused in this population. Objective: The goal of this review is to evaluate the role of insulin therapy in elderly patients and identify strategies to improve its use in this patient population. Methods: Searches of the MEDLINE and EMBASE databases were conducted to identify papers published in English between January 1990 and March 2010. The following search terms were used: diabetes mellitus, insulin, elderly, geriatric, analog, premix, pen device, and human insulin. Papers selected for review included meta-analyses, randomized controlled trials of insulin therapy, or evidence-based reviews and/or expert opinion regarding the use of insulin in elderly patients with diabetes. Results: Insulin therapy is the most effective antidiabetic agent when appropriately dosed; however, only a minority of elderly patients with diabetes uses it. Although there are few randomized controlled studies on insulin use in the elderly, an individualized approach to insulin therapy is recommended to account for varying clinical and practical factors that affect diabetes care in this patient population. Therapy with insulin analogs offers several advantages compared with human insulin regimens, including a more physiologic pharmacologic profile, increased convenience, and a reduced risk of hypoglycemia, which may make them particularly attractive in older adults. Premixed insulin analog therapy may provide added convenience, as well as improved glycemic control. Insulin pen devices are also recommended to facilitate insulin dosing and help patients maintain their independence. Conclusions: The improved clinical profiles of insulin analogs and the ease of use of newer insulin delivery devices may be advantageous in elderly patients with diabetes; however, additional research on the efficacy and safety of insulin regimens is urgently needed. © 2011 Elsevier HS Journals, Inc.